Geode Capital Management LLC Purchases 61,582 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Geode Capital Management LLC boosted its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 10.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 643,342 shares of the company’s stock after buying an additional 61,582 shares during the quarter. Geode Capital Management LLC’s holdings in scPharmaceuticals were worth $2,934,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Rubric Capital Management LP lifted its position in shares of scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp grew its holdings in scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after buying an additional 20,650 shares during the last quarter. Suvretta Capital Management LLC bought a new stake in shares of scPharmaceuticals in the third quarter valued at approximately $9,343,000. Thrivent Financial for Lutherans grew its stake in shares of scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after acquiring an additional 14,866 shares during the last quarter. Finally, Stonepine Capital Management LLC grew its stake in shares of scPharmaceuticals by 84.7% in the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after acquiring an additional 357,171 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Stock Down 1.7 %

Shares of SCPH stock opened at $3.56 on Wednesday. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.54. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock has a fifty day moving average price of $3.61 and a 200 day moving average price of $4.30. The stock has a market cap of $178.14 million, a P/E ratio of -1.87 and a beta of 0.11.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SCPH shares. Craig Hallum reduced their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.